Sorted By Test Name - Mayo Medical Laboratories

IDST
8780
categorized into 3 syndromes: Hurler syndrome (MPS IH), Scheie syndrome (MPS IS), and Hurler-Scheie
syndrome (MPS IH/S). Because these syndromes cannot be distinguished biochemically, they are also
referred to as MPS I and attenuated MPS I. Clinical features and severity of symptoms of MPS I are
variable, ranging from severe disease to an attenuated form that generally presents at a later onset with a
milder clinical presentation. In general, symptoms may include coarse facies, progressive dysostosis
multiplex, hepatosplenomegaly, corneal clouding, hearing loss, intellectual disabilities or learning
difficulties, and cardiac valvular disease. The incidence of MPS I is approximately 1 in 100,000 live
births. Treatment options include hematopoietic stem cell transplantation and enzyme replacement
therapy. A diagnostic workup in an individual with MPS I typically demonstrates elevated levels of
urinary GAG (MPSQN/81473 Mucopolysaccharides [MPS], Quantitative, Urine) and increased amounts
of both dermatan and heparan sulfate detected on thin-layer chromatography (MPSSC/84464
Mucopolysaccharides [MPS] Screen, Urine). Reduced or absent activity of alpha-L-iduronidase in blood
spots, fibroblasts (IDST/8780 Alpha-L-Iduronidase, Fibroblasts), leukocytes, or whole blood
(IDSWB/60618 Alpha-L-Iduronidase, Blood) can confirm a diagnosis of MPS I; however, enzymatic
testing is not reliable for carrier detection. Molecular sequence analysis of the IDUA gene allows for
detection of the disease-causing mutation in affected patients and subsequent carrier detection in relatives.
To date, a clear genotype-phenotype correlation has not been established.
Useful For: Diagnosis of mucopolysaccharidosis I, Hurler, Scheie, and Hurler-Scheie syndromes using
dried blood spot specimens
Interpretation: Specimens with results or =1.0
nmol/hour/mL) are not consistent with alpha-L-iduronidase deficiency.
Reference Values:
> or =1.0 nmol/h/mL
An interpretive report will be provided.
Clinical References: 1. Neufeld EF, Muenzer J: The mucopolysaccharidoses. In The Metabolic and
Molecular Basis of Inherited Disease. Vol 3. 8th edition. Edited by CR Scriver, AL Beaudet, WS Sly, et
al. McGraw-Hill, Medical Publishing Division, 2001, p 3421 2. Chamoles NA, Blanco M, Gaggioli D,
Casentini C: Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem
2001;47:2098-2102 3. Martins AM, Dualibi AP, Norato D, et al: Guidelines for the management of
mucopolysaccharidosis type I. J Pediatr 2009 Oct:155(4 Suppl):S32-S46 4. Enns GM, Steiner RD, Cowan
TM: Lysosomal disorders: mucopolysaccharidoses. In Pediatric Endocrinology and Inborn Errors of
Metabolism. Edited by K Sarafoglou, GF Hoffmann, KS Roth. McGraw-Hill, Medical Publishing
Division, 2009, pp 721-730 5. Clarke LA, Heppner J: Mucopolysaccharidosis Type I. GeneReviews.
Edited by RA Pagon, TD Bird, CR Dolan, et al. University of Washington, Seattle. Last updated July
2011
Alpha-L-Iduronidase, Fibroblasts
Clinical Information: The mucopolysaccharidoses are a group of lysosomal storage disorders caused
by the deficiency of any of the enzymes involved in the stepwise degradation of dermatan sulfate, heparan
sulfate, keratan sulfate, or chondroitin sulfate (glycosaminoglycans; GAG). Accumulation of GAG
(previously called mucopolysaccharides) in lysosomes interferes with normal functioning of cells, tissues,
and organs. Mucopolysaccharidosis I (MPS I) is an autosomal recessive disorder caused by a reduced or
absent activity of the alpha-L-iduronidase enzyme. Deficiency of the alpha-L-iduronidase enzyme can
result in a wide range of phenotypes further categorized into 3 syndromes: MPS IH (Hurler syndrome),
MPS IS (Scheie syndrome), and MPS IH/S (Hurler-Scheie syndrome). Because there is no way to
distinguish the syndromes biochemically, they are also referred to as MPS I and attenuated MPS I.
Clinical features and severity of symptoms of MPS I are widely variable, ranging from severe disease to
an attenuated form that generally presents at a later onset with a milder clinical presentation. Symptoms
typically include coarse facies, progressive dysostosis multiplex, hepatosplenomegaly, corneal clouding,
hearing loss, mental retardation or learning difficulties, and cardiac valvular disease. The incidence of
MPS I is approximately 1 in 100,000 live births. Treatment options include hematopoietic stem cell
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 96